Edition:
United Kingdom

People: Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

55.92USD
23 Aug 2019
Change (% chg)

$-2.30 (-3.95%)
Prev Close
$58.22
Open
$58.42
Day's High
$58.49
Day's Low
$55.64
Volume
60,055
Avg. Vol
67,775
52-wk High
$82.33
52-wk Low
$36.10

Meyers, Pete 

Mr. Pete A. Meyers has been appointed as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer of the Eagle Pharmaceuticals Inc. Mr. Meyers served as the Chief Financial Officer of Motif BioSciences Inc., where he led the execution of the company's November 2016 U.S. initial public offering. From August 2013 to March 2016, Mr. Meyers served as Chief Financial Officer and Treasurer of TetraLogic Pharmaceuticals Corporation, where he led the execution of the company's December 2013 initial public offering and subsequent acquisition of Shape Pharmaceuticals, Inc. Prior to his role at TetraLogic, Mr. Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read & Co., Credit Suisse First Boston LLC and, most recently, as Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. Mr. Meyers currently serves on the Board of Directors of Immutep Ltd, where he chairs the audit committee. Mr. Meyers is also the Chairman and President of The Thomas M. Brennan Memorial Foundation, Inc. Mr. Meyers holds a B.S. in finance from Boston College and an M.B.A. from Columbia Business School.

Basic Compensation

Total Annual Compensation, USD 412,000
Restricted Stock Award, USD 1,045,310
Long-Term Incentive Plans, USD --
All Other, USD 1,216,540
Fiscal Year Total, USD 2,673,850

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Michael Graves

392,278

David Pernock

3,675,440

Scott Tarriff

11,324,500

Pete Meyers

2,673,850

Adrian Hepner

3,134,840

Douglas Braunstein

319,778
As Of  31 Dec 2018